Retroviral vectors
OwnerAlan John Kingsman, Miles William Carroll +3inventors
InventorsAlan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim
Life of this patent
Estimating the term…
Abstract
A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.
Claims29
A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.
A retroviral vector derived from a non-primate lentivirus genome wherein one or more accessory genes are absent from the non-primate lentivirus genome.
A retroviral vector derived from a lentivirus genome wherein the non-primate lentivirus genome lacks the tat gene but includes the leader sequences between the end of the 5′ LTR and the ATG of gag.
A retroviral vector according to any preceding claim which comprises at least one component from an equinine lentivirus.
A retroviral vector production system for producing the retroviral vector of any preceding claim comprising a packaging cell comprising a gag-pol gene from a non-primate lentivirus and an envelope gene.
A hybrid viral vector system comprising a primary viral vector derived from a poxvirus and a second viral vector derived from a retrovirus.
A retroviral vector substantially as hereinbefore described with reference to the accompanying Figures.
A retroviral vector production system substantially as hereinbefore described with reference to the accompanying Figures.
A retroviral particle substantially as hereinbefore described with reference to the accompanying Figures.
A cell transfected or transduced with a retroviral vector substantially as hereinbefore described with reference to the accompanying Figures.
Use of a retroviral vector substantially as hereinbefore described with reference to the accompanying Figures.
A method comprising transfecting or transducing a cell with a retroviral vector substantially as hereinbefore described with reference to the accompanying Figures.
A delivery system in the form of a retroviral vector substantially as hereinbefore described with reference to the accompanying Figures.
Dependencies are inferred from the claim text.